Movement Alert｜Joinn Laboratories Rises 6.9% in Regular Trading, H1 Profit Forecast Surges Up to 1377% Amid CXO Sector Rally

Market Focus07-20

On July 20, Joinn Laboratories (06127.HK) rose 6.9% in regular trading, trading at HK$25.06 per share, with turnover of HK$203 million.

On the news front, the company previously disclosed its H1 earnings guidance, projecting attributable net profit of RMB 600 million to RMB 900 million, representing year-over-year growth of 884.9% to 1,377.4%. The surge was primarily driven by biological asset fair value changes contributing approximately RMB 703 million to RMB 777 million in net profit, as experimental monkey market prices broke through RMB 200,000 per unit combined with natural growth appreciation.

Meanwhile, the broader CXO sector continued its rebound trend, with peers including WuXi Biologics, Pharmaron, and WuXi XDC posting broad gains on the day. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 3.53%, WUXI BIO gained 4.65%, INSILICO advanced 5.14%, PHARMARON climbed 5.95%, and WUXI XDC added 5.44%, reflecting improving sector sentiment that provided additional support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179474506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179474506","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Joinn Laboratories Rises 6.9% in Regular Trading, H1 Profit Forecast Surges Up to 1377% Amid CXO Sector Rally","media":"Market Focus","content":"<p><p>On July 20, Joinn Laboratories (06127.HK) rose 6.9% in regular trading, trading at HK$25.06 per share, with turnover of HK$203 million.</p><p>On the news front, the company previously disclosed its H1 earnings guidance, projecting attributable net profit of RMB 600 million to RMB 900 million, representing year-over-year growth of 884.9% to 1,377.4%. The surge was primarily driven by biological asset fair value changes contributing approximately RMB 703 million to RMB 777 million in net profit, as experimental monkey market prices broke through RMB 200,000 per unit combined with natural growth appreciation.</p><p>Meanwhile, the broader CXO sector continued its rebound trend, with peers including WuXi Biologics, Pharmaron, and WuXi XDC posting broad gains on the day. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 3.53%, WUXI BIO gained 4.65%, INSILICO advanced 5.14%, PHARMARON climbed 5.95%, and WUXI XDC added 5.44%, reflecting improving sector sentiment that provided additional support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Joinn Laboratories Rises 6.9% in Regular Trading, H1 Profit Forecast Surges Up to 1377% Amid CXO Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Joinn Laboratories Rises 6.9% in Regular Trading, H1 Profit Forecast Surges Up to 1377% Amid CXO Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, Joinn Laboratories (06127.HK) rose 6.9% in regular trading, trading at HK$25.06 per share, with turnover of HK$203 million.</p><p>On the news front, the company previously disclosed its H1 earnings guidance, projecting attributable net profit of RMB 600 million to RMB 900 million, representing year-over-year growth of 884.9% to 1,377.4%. The surge was primarily driven by biological asset fair value changes contributing approximately RMB 703 million to RMB 777 million in net profit, as experimental monkey market prices broke through RMB 200,000 per unit combined with natural growth appreciation.</p><p>Meanwhile, the broader CXO sector continued its rebound trend, with peers including WuXi Biologics, Pharmaron, and WuXi XDC posting broad gains on the day. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 3.53%, WUXI BIO gained 4.65%, INSILICO advanced 5.14%, PHARMARON climbed 5.95%, and WUXI XDC added 5.44%, reflecting improving sector sentiment that provided additional support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"","article_id":"1179474506","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179474506","pubTimestamp":1784513023,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, Joinn Laboratories (06127.HK) rose 6.9% in regular trading, trading at HK$25.06 per share, with turnover of HK$203 million.On the news front, the company previously disclosed its H1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06127":"昭衍新药"},"translate_title":"走势警报|Joinn Laboratories 常规交易上涨 6.9%，上半年利润预测在 CXO 板块反弹中飙升至 1377%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06127":1},"content_text":"On July 20, Joinn Laboratories (06127.HK) rose 6.9% in regular trading, trading at HK$25.06 per share, with turnover of HK$203 million.On the news front, the company previously disclosed its H1 earnings guidance, projecting attributable net profit of RMB 600 million to RMB 900 million, representing year-over-year growth of 884.9% to 1,377.4%. The surge was primarily driven by biological asset fair value changes contributing approximately RMB 703 million to RMB 777 million in net profit, as experimental monkey market prices broke through RMB 200,000 per unit combined with natural growth appreciation.Meanwhile, the broader CXO sector continued its rebound trend, with peers including WuXi Biologics, Pharmaron, and WuXi XDC posting broad gains on the day. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 3.53%, WUXI BIO gained 4.65%, INSILICO advanced 5.14%, PHARMARON climbed 5.95%, and WUXI XDC added 5.44%, reflecting improving sector sentiment that provided additional support.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179474506","isCrawlerRequest":true}